Radisens’ addressable niche is in excess of $8 billion, growing at 15% annually. Radisens is developing a single instrument to test for multiple diseases that requires only a single drop of blood and can be performed and interpreted by any general physician within minutes. No such solution currently exists; various companies have developed instruments which only part-test separately for some blood ailments and diseases. The Radisens solution will enable test results to be shared instantaneously with patients for chronic conditions (diabetes, hypertension, chronic kidney disease), infectious diseases, thyroid function, early cancers, cardiac ailments and virus diagnosis, uniquely targeting both chronic and acute point-of-care markets. We have significant market traction, have completed trials of our early platforms and are already engaged with the majority of the top ten diagnostic multinationals companies.

Current Investors

The company is funded by the promoters, private angels, Cork City Enterprise Board, Sophia Business Angels and Enterprise Ireland. If you are a private business angel or institutional investors interested in investing, please talk to us to discuss the opportunity in more detail.

You will find a further outline in our market and technology sections. Due to the commercially sensitive nature of our product roadmap and business development, this outline is necessarily broad. Additional confidential information about our technology, sales & marketing strategy and financials is available offline through discussion with our experienced management team.